A landmark Phase 3 trial has delivered the first positive result for Stargardt disease treatment — but the therapeutic landscape is shifting fast. Prof. Maximilian Pfau enjoys a discussion with Prof. Carel Hoyng and Dr. Karolina Kaminska on the ABCA4 disease spectrum, the groundbreaking discovery of AP5 complex-related macular dystrophy, and emerging therapies from oral drugs to gene-specific approaches